EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Colin J. Meyer, MDEmployment Agreement • October 19th, 2015 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 23rd day September of 2015, by and between Reata Pharmaceuticals, Inc., a Delaware corporation (together with its successors and assigns permitted hereunder, the “Company”), and Colin J. Meyer, MD (the “Executive”).
REATA PHARMACEUTICALS, INC. EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 19th, 2015 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
This EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of the 6th day of December, 2011, by and among REATA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), the parties listed on the signature pages hereto, the Investors (as defined herein) listed on Schedule A hereto, University of Texas System (“UT System”), and the stockholders of the Company listed on Schedule B hereto (the “Other Stockholders”).
LEASE SDCO GATEWAY COMMERCE I & II, INC., Landlord, and REATA PHARMACEUTICALS, INC., TenantLease • October 19th, 2015 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
By this Lease Landlord leases to Tenant and Tenant leases from Landlord the Premises in the Building as set forth and described on the Reference Pages. The Premises are depicted on the floor plan attached hereto as Exhibit A, and the Building is depicted on the site plan attached hereto as Exhibit A-1. The Reference Pages, including all terms defined thereon, are incorporated as part of this Lease.
REATA PHARMACEUTICALS, INC. SEVENTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 19th, 2015 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
This SEVENTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of the 10th day of November, 2010, by and among REATA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), the Investors (as defined herein), and University of Texas System (“UT System”).
